AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22508732 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 84
Study 22508732 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 84
Study 20187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance respiratory muscle training (RRMT) performed every 30 s against spring loaded inspiratory and expiratory valves 30 min/day, 5 days/week, for 4 weeks.
Number of subjects: 8
Study 20187286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance respiratory muscle training (RRMT)
Number of subjects: 8
Study 18853581 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sodium bicarbonate
Number of subjects: 0
Study 16848109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized cow milk yogurt (15 ml/kg/day) plus routine hospital treatment
Number of subjects: 80
Study 16848109 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital treatment
Number of subjects: 80
Study 14685931 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 and BL67 acupressure
Number of subjects: 127
Study 14685931 — intervention group
Group type: COMPARATOR
Intervention: Light skin stroking
Number of subjects: 127
Study 14685931 — intervention group
Group type: COMPARATOR
Intervention: No treatment/conversation only
Number of subjects: 127
Study 10973843 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine, with possible addition of enalapril, hydrochlorothiazide, or both)
Number of subjects: 0
Study 10973843 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 10973843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9261659 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial binge eating
Number of subjects: 108
Study 9261659 — intervention group
Group type: COMPARATOR
Intervention: Initial dieting
Number of subjects: 108
Study 9261659 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial binge eaters
Number of subjects: 108
Study 8451663 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component acellular pertussis vaccine (LPF/FHA)
Number of subjects: 145
Study 8451663 — intervention group
Group type: COMPARATOR
Intervention: Standard whole-cell pertussis vaccine
Number of subjects: 145
Study 2434108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered human pepsinated immunoglobulin G (HPIG, Gamma‐Venin)
Number of subjects: 0
Study 2434108 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment or intervention was used)
Number of subjects: 0
Study 30259623 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 mcg
Number of subjects: 6
Study 30259623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 6
Study 28845751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061
Study 28845751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 28845751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061
Study 28845751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 25796269 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated tobacco control and occupational safety and health program
Number of subjects: 20
Study 25796269 — intervention group
Group type: COMPARATOR
Intervention: Control companies
Number of subjects: 20
Study 23462720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy with cisplatin and paclitaxel
Number of subjects: 393
Study 23462720 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy with paclitaxel and cisplatin
Number of subjects: 393
Study 21289328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 21289328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (in patients with serum sodium concentration of <130 meq/L)
Number of subjects: 0
Study 21289328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in hyponatremic patients)
Number of subjects: 0
Study 21289328 — intervention group
Group type: COMPARATOR
Intervention: More severely hyponatremic patients (serum sodium concentration of <135 meq/L) receiving placebo
Number of subjects: 0
Study 19260800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg administered 1 hour before SWL and 24 hours later
Number of subjects: 69
Study 19260800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment medications)
Number of subjects: 69
Study 19260800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 69
Study 17105757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg daily, increased to 30 mg and then to 60 mg if necessary)
Number of subjects: 448
Study 17105757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 17105757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 448
Study 14675982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0
Study 14675982 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 14675982 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 0
Study 11502641 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2)WT
Number of subjects: 20
Study 11502641 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2) administration
Number of subjects: 20
Study 11502641 — intervention group
Group type: COMPARATOR
Intervention: BWT
Number of subjects: 20
Study 11502641 — intervention group
Group type: COMPARATOR
Intervention: CAWT
Number of subjects: 20
Study 9010043 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 63
Study 9010043 — intervention group
Group type: COMPARATOR
Intervention: CODE alone
Number of subjects: 63
Study 8303624 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0679 (825 mg, orally)
Number of subjects: 8
Study 8303624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3706879 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (AS) 6.4 mg total (3.2 mg inhaled twice)
Number of subjects: 21
Study 3706879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (MP) 30 mg total (15 mg inhaled twice)
Number of subjects: 21
Study 30928806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2, intravenously, on day 1 and day 8)
Number of subjects: 530
Study 30928806 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2, intravenously, on day 1, day 8 and day 15)
Number of subjects: 530
Study 30928806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 530
Study 30928806 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 530
Study 28601821 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab plus celecoxib
Number of subjects: 0
Study 28601821 — intervention group
Group type: COMPARATOR
Intervention: Golimumab alone
Number of subjects: 0
Study 25650561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided modeling intervention with contrastive targets through concentrated modeling and interactive play activities.
Number of subjects: 3
Study 25650561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided modeling intervention with contrastive targets.
Number of subjects: 3
Study 23229908 — intervention group
Group type: EXPERIMENTAL
Intervention: Too much perceived decision-making responsibility
Number of subjects: 368
Study 23229908 — intervention group
Group type: EXPERIMENTAL
Intervention: Not enough perceived decision-making responsibility
Number of subjects: 368
Study 23229908 — intervention group
Group type: COMPARATOR
Intervention: Reasonable amount of perceived decision-making responsibility
Number of subjects: 368
Study 22084195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10(6) autologous bone marrow mononuclear cells (BMCs)
Number of subjects: 87
Study 22084195 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 87
Study 22084195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10(6) autologous BMCs
Number of subjects: 87
Study 19407945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dripping of Qingkailing Injection in combination with oral intake of Er'tong Qingfei Oral Liquid
Number of subjects: 206
Study 19407945 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dripping of ribavirin injection in combination with oral intake of potassium guaiacol sulfonate oral liquid
Number of subjects: 206
Study 16465090 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Competencies for RNs in Hospitals
Number of subjects: 0
Study 14671151 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-300 microTesla, 50 Hz circularly polarized magnetic field for 2 hours
Number of subjects: 19
Study 14671151 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 19
Study 10736973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days)
Number of subjects: 18
Study 10736973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.)
Number of subjects: 18
Study 10736973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus MCP (2.5 mg in an i.v. bolus injection)
Number of subjects: 18
Study 10736973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.) plus MCP (2.5 mg in an i.v. bolus injection)
Number of subjects: 18
Study 10736973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9119934 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 0
Study 9119934 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical groups (autism, MR, Down syndrome)
Number of subjects: 0
Study 9119934 — intervention group
Group type: EXPERIMENTAL
Intervention: MR group
Number of subjects: 0
Study 9119934 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with autism
Number of subjects: 0
Study 9119934 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with MR
Number of subjects: 0
Study 1353742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml HiEPA fish oil (4.5 g of eicosapentaenoic acid) daily for one year
Number of subjects: 87
Study 1353742 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo daily for one year
Number of subjects: 87
Study 1353742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml HiEPA fish oil
Number of subjects: 87
Study 6233921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms, three doses)
Number of subjects: 1330
Study 6233921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1330
Study 31525488 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific communication tools (website, brochure, posters, signboard)
Number of subjects: 2100
Study 29589873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202
Study 29589873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 202
Study 29589873 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 202
Study 27305424 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine group (50μg fentanyl before colonoscopy)
Number of subjects: 119
Study 27305424 — intervention group
Group type: COMPARATOR
Intervention: On-demand group (50μg fentanyl if needed during colonoscopy)
Number of subjects: 119
Study 27305424 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine group
Number of subjects: 119
Study 27305424 — intervention group
Group type: COMPARATOR
Intervention: On-demand group
Number of subjects: 119
Study 24801452 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial compliance (C T)
Number of subjects: 279
Study 24801452 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-to-femoral pulse wave velocity (PWV)
Number of subjects: 279
Study 22443122 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion
Number of subjects: 240
Study 22443122 — intervention group
Group type: COMPARATOR
Intervention: ZirLiner application
Number of subjects: 240
Study 22443122 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment
Number of subjects: 240
Study 22443122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic loading
Number of subjects: 240
Study 20602892 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients supplement
Number of subjects: 102
Study 20602892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18614731 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake ranging from 10 to 120 mg x kg(‐1) x d(‐1)
Number of subjects: 15
Study 16372879 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer vaccines
Number of subjects: 0
Study 16372879 — intervention group
Group type: COMPARATOR
Intervention: Standard breast cancer drugs or novel immunotherapeutics
Number of subjects: 0
Study 12296776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 17
Study 12296776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonactivated laser)
Number of subjects: 17
Study 10570638 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 16
Study 8842630 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM (Composite International Diagnostic Interview‐Substance Abuse Module)
Number of subjects: 0
Study 8842630 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM/SAM (test/retest)
Number of subjects: 0
Study 8842630 — intervention group
Group type: COMPARATOR
Intervention: SAM/SCAN (test/validation)
Number of subjects: 0
Study 2065809 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% serum
Number of subjects: 194
Study 2065809 — intervention group
Group type: COMPARATOR
Intervention: 8% serum
Number of subjects: 194
Study 2065809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25% human serum albumin (HSA)
Number of subjects: 194
Study 6306094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 6306094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6306094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and antacids
Number of subjects: 0
Study 30702996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, gemcabene
Number of subjects: 0
Study 30702996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alipogene tiparvovec, pradigastat, volanesorsen
Number of subjects: 0
Study 30702996 — intervention group
Group type: EXPERIMENTAL
Intervention: evinacumab, IONIS‐ANGPTL3‐LRx
Number of subjects: 0
Study 30702996 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)‐LRx
Number of subjects: 0
Study 29389671 — intervention group
Group type: COMPARATOR
Intervention: Primaquine (15 mg, n = 5)
Number of subjects: 17
Study 29389671 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel (500 mg, n = 4)
Number of subjects: 17
Study 29389671 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n = 7)
Number of subjects: 17
Study 26067095 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during invasive nursing procedures
Number of subjects: 138
Study 26067095 — intervention group
Group type: COMPARATOR
Intervention: No family presence during invasive nursing procedures (Control)
Number of subjects: 138
Study 25115438 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of 2000 IU of vitamin D3 per day
Number of subjects: 0
Study 25115438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dosing of 40,000 IU of vitamin D3 per month
Number of subjects: 0
Study 22289281 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (50 μg/kg/min)
Number of subjects: 60
Study 22289281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.01 μg/kg/min)
Number of subjects: 60
Study 22289281 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional anesthetic drugs and 20 ml/kg of lactated Ringer's over 30 mins)
Number of subjects: 60
Study 19285832 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training alone or supervised practice prior to home training
Number of subjects: 13
Study 19285832 — intervention group
Group type: COMPARATOR
Intervention: Supervised practice
Number of subjects: 13
Study 19285832 — intervention group
Group type: COMPARATOR
Intervention: Home training
Number of subjects: 13
Study 17254365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of behavioural treatment (n=16)
Number of subjects: 31
Study 17254365 — intervention group
Group type: COMPARATOR
Intervention: Repeated assessments (RA; n=15)
Number of subjects: 31
Study 15008926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of ITI implants (2 weeks after placement)
Number of subjects: 27
Study 15008926 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 weeks after placement)
Number of subjects: 27
Study 11079508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (LSD)
Number of subjects: 16
Study 11079508 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal salt diet (NSD)
Number of subjects: 16
Study 11079508 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (HSD)
Number of subjects: 16
Study 11079508 — intervention group
Group type: COMPARATOR
Intervention: Control group (without EIA)
Number of subjects: 16
Study 9589363 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg oltipraz daily
Number of subjects: 234
Study 9589363 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oltipraz weekly
Number of subjects: 234
Study 9589363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 8448097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Volume (LV) group: 1.5 to 2 mL per hour of bupivacaine 0.5% with sufentanil 4 micrograms/mL
Number of subjects: 30
Study 8448097 — intervention group
Group type: COMPARATOR
Intervention: High Volume (HV) group: 6 to 8 mL per hour of bupivacaine 0.125% with sufentanil 1 microgram/mL
Number of subjects: 30
Study 8448097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 2427843 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily
Number of subjects: 100
Study 2427843 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 100
Study 2427843 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 600 mg once daily
Number of subjects: 100
Study 2427843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3384951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals containing 0, 8, 16, 24, and 32 kcal/kg fat‐free mass
Number of subjects: 0
Study 3384951 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake
Number of subjects: 0
Study 31145324 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered educational strategy
Number of subjects: 170
Study 31145324 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 170
Study 28450552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary arteries (BIMA)
Number of subjects: 3102
Study 28450552 — intervention group
Group type: COMPARATOR
Intervention: Single internal mammary arteries (SIMA)
Number of subjects: 3102
Study 28450552 — intervention group
Group type: EXPERIMENTAL
Intervention: BIMA
Number of subjects: 3102
Study 26212007 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV-HD
Number of subjects: 31989
Study 26212007 — intervention group
Group type: COMPARATOR
Intervention: IIV-SD
Number of subjects: 31989
Study 23294052 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (olanzapine + fluoxetine)
Number of subjects: 994
Study 23294052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 21464252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 300 mg/day
Number of subjects: 37
Study 21464252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 600 mg/day
Number of subjects: 37
Study 21464252 — intervention group
Group type: COMPARATOR
Intervention: Safety analysis set (42 patients)
Number of subjects: 37
Study 18349029 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX + Cetuximab
Number of subjects: 74
Study 18349029 — intervention group
Group type: COMPARATOR
Intervention: XELOX
Number of subjects: 74
Study 17998674 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (6500 cGy/30 fractions)
Number of subjects: 103
Study 17998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin 80 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1-3, q3 weeks for 3 cycles) followed by radiotherapy (6000 cGy/30 fractions) and 3 more cycles of the same chemotherapy regimen
Number of subjects: 103
Study 17998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (5000 cGy/25 fractions) with concurrent chemotherapy (cisplatin 20 mg/m2 + Etoposide 75 mg/m2 on days 1-5 and days 22-26), followed by 2 more cycles of chemotherapy, q3 weeks with the same regimen
Number of subjects: 103
Study 12737444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral budesonide (3 mg three times daily for 8 days)
Number of subjects: 20
Study 11090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis at the PA spine
Number of subjects: 1494
Study 11090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis at the femoral neck
Number of subjects: 1494
Study 11090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis at the midforearm
Number of subjects: 1494
Study 11090233 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD cutoff levels for osteoporosis
Number of subjects: 1494
Study 11090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper cutoff level for osteopenia
Number of subjects: 1494
Study 9198795 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves
Number of subjects: 0